Fig. 5

STAT3 is required for L1CAM-driven clonogenic advantage and is a suitable target both in vitro and in vivo. (A) Ov90-mock and Ov90-L1CAM cells were treated with the indicated concentration of Napabucasin and subjected to sphere formation assay. (B) SFE assay in Ov90-mock and Ov90-L1CAM cells treated with Napabucasin (50 nM) and paclitaxel (6 nM), either alone or in combination. For each analysis, data are expressed as means ± SEM from three independent experiments. Comparisons between experimental groups were done with two-sided Student’s t-tests. (C) Kaplan-Meier curves showing tumor volume over time in mice treated with Napabucasin upon subcutaneous injection of either Ov90-mock or Ov90-L1CAM cells. Tumor volume equal to 400 mm³ was defined as data censoring criterion. Comparisons between experimental groups were done with Log-rank (Mantel-Cox) test; *p < 0.05, ***p < 0.001; ns = not significant